Question 1

Why did Pryme One plant operations stop in March?

Accepted Answer

Pryme One plant ceased operations in March due to problems with reactor technology.

Question 2

What is EMV Capital’s direct equity stake in DeepTech Recycling?

Accepted Answer

EMV Capital holds an 18% direct equity stake in DeepTech Recycling and manages a further 31% on behalf of third-party investors.

Question 3

What assets did Moirai Acquisitions (renamed AMR Bio) acquire from Destiny Pharma in September 2025?

Accepted Answer

In September 2025, Moirai Acquisitions (renamed AMR Bio) acquired XF-73 assets from Destiny Pharma, including an IND for XF-73 Nasal, a pIND for XF-73 Dermal, QIDP designation, and FDA Fast Track status.

Question 4

How much debt was used to fund EMV Capital’s 14 September 2026 acquisition of the Pryme One plant?

Accepted Answer

The Pryme One plant acquisition was funded entirely through third-party debt syndicated by EMV Capital Partners. The funding included about a £1.7m 30-month term loan (extendable to ~£3m) and about a £0.3m 6-month unsecured loan.

Question 5

What is required to reopen the Pryme One plant?

Accepted Answer

Reopening depends on a successful technical retrofit using DeepTech Recycling’s proprietary reactor, requiring about £6 million of additional capital expenditure and funding plus commercial terms, including a first commercial-scale customer/reference site in Rotterdam’s Plant One cluster.

Question 6

What plastic waste chemical recycling plant did EMV Capital acquire in Rotterdam on 14 September 2026?

Accepted Answer

On 14 September 2026, EMV Capital acquired the Pryme One plastic waste chemical recycling plant in Rotterdam via a new subsidiary, Winalot BV. Winalot bought the plant and related assets, including IP, from Pryme.

Timeline

Emv Capital

EMV Capital acquires Rotterdam recycling plant via new venture

EMV Capital portfolio companies Glycotest and ProAxsis raise fresh equity

EMV Capital commercial update spotlights XF-73 as it moves toward Phase 3

More in Biotech

IP Group leads £4m funding round for AI materials spin-out

Genflow wins Japanese patent allowance for SIRT6 therapy

Scancell widens annual loss

Sareum signals intention to launch equity capital raise

OKYO Pharma enrolls first patients in Phase 3 neuropathic corneal pain trial

Poolbeg Pharma secures South Korean patent for POLB 001

Avacta raises £12.5m in placing and subscription

Health & Bio Today: Fusion Antibodies refreshes platform after margin turnaround, Molecule Group

Fusion Antibodies relaunches website to sharpen customer focus

Cardiogeni shares suspended on delayed annual accounts

Imaging Biometrics builds US pipeline, rebrands core platform as IB Vista

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer